| abstract |
the present invention generally relates to the field of therapeutic compounds. more specifically, the present invention relates to certain compounds of 4 - [[(7-aminopyrazolo [1,5-a] pyrimidin-5-yl) amino] methyl] piperidin-3-ol (referred to herein as "compounds of appamp ") that, among others, inhibit (for example, selectively inhibit) cdk (e.g., cdk1, cdk2, cdk4, cdk5, cdk6, cdk7, cdk8, cdk9, cdk10, cdk11, cdk12, cdk13, etc.). the present invention likewise relates to pharmaceutical compositions comprising such compounds and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cdk; and to treat disorders, including: disorders associated with cdk; disorders that result in inappropriate activity of a cyclin-dependent kinase (cdk); disorders associated with the cdk mutation; disorders associated with cdk overexpression; disorders that are associated with the activation of the cdk on the upstream trail; disorders that are ameliorated by inhibition of cdk; proliferative disorders; cancer; viral infections (including hiv); neurodegenerative disorders (including alzheimer's disease and parkinson's disease); ischemia; kidney disease; cardiovascular disease (including atherosclerosis); and autoimmune disorders (including rheumatoid arthritis). optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with an additional active agent which is, for example, an aromatase inhibitor, an antiestrogen, a her2 blocker, a cytotoxic chemotherapeutic agent, etc. |